logies.Optimisation must be carried out on all medical radiological units to ensure doses are as low as reasonably practicable, consistent with the intended purpose. To achieve this, population doses must be estimated and diagnostic reference levels (DRLs) set. For mammography examinations, mean glandular doses (MGDs) are calculated for this purpose. The average MGD per unit is compared to the national mammography DRL, which is applicable to compressed breast thicknesses (CBTs) of 50-60 mm for oblique (OB) views only and set using data from screening units. It is the purpose of this work to assess planar MGDs across Scotland and set DRLs based on data collected from all screening and symptomatic units across Scotland, considering craniocaudal (CC) and OB views and a wider range of CBTs. Data from the most recent dose audit (spanning 2015-2017) for 67 mammography x-ray units were collated and analysed (26 195 images). No large differences between MGD of CC and OB views were found when considering specific CBT ranges (median difference 2.6%). There was, however, a significant difference between screening and symptomatic data (19%). As expected, MGD increased with CBT and there were significant differences in MGD between manufacturers. From the data analysed, Scottish DRLs were set based on 95th percentile values for digital mammography units for three CBT ranges (30-49, 50-60 and 61-80 mm) 1.3, 1.8 and 2.6 mGy respectively. These values consider OB and CC views collectively. Fifth percentile values are quoted to highlight units at greater risk of insufficient image quality. These MGD values, together with image quality assessments, will facilitate optimisation across Scotland. Results show that use of different CBT ranges and inclusion of CC views increases the number of images included in dose audit data analysis from approximately 12%-92%, which is substantially more representative of the population.Understanding the movement of antimicrobial resistance genes (ARGs) in the environment is critical to managing their spread. To assess potential ARG transport through the air via urban bioaerosols in cities with poor sanitation, we quantified ARGs and a mobile integron (MI) in ambient air over periods spanning rainy and dry seasons in Kanpur, India (n = 53), where open wastewater canals (OCWs) are prevalent. Gene targets represented major antibiotic groups-tetracyclines (tetA), fluoroquinolines (qnrB), and beta-lactams (blaTEM)-and a class 1 mobile integron (intI1). Over half of air samples located near, and up to 1 km from OCWs with fecal contamination (n = 45) in Kanpur had detectable targets above the experimentally determined limits of detection (LOD) most commonly intI1 and tetA (56% and 51% of samples, respectively), followed by blaTEM (8.9%) and qnrB (0%). ARG and MI densities in these positive air samples ranged from 6.9 × 101 to 5.2 × 103 gene copies/m3 air. Most (7/8) control samples collected 1 km away from OCWs were negative for any targets. In comparing experimental samples with control samples, we found that intI1 and tetA densities in air are significantly higher (P = 0.04 and P = 0.01, respectively, alpha = 0.05) near laboratory-confirmed fecal contaminated waters than at the control site. These data suggest increased densities of ARGs and MIs in bioaerosols in urban environments with inadequate sanitation. In such settings, aerosols may play a role in the spread of AR.The first case of COVID-19 in sub-Saharan Africa (SSA) was reported by Nigeria on February 27, 2020. Whereas case counts in the entire region remain considerably less than those being reported by individual countries in Europe, Asia, and the Americas, variation in preparedness and response capacity as well as in data availability has raised concerns about undetected transmission events in the SSA region. To capture epidemiological details related to early transmission events into and within countries, a line list was developed from publicly available data on institutional websites, situation reports, press releases, and social media accounts. The availability of indicators-gender, age, travel history, date of arrival in country, reporting date of confirmation, and how detected-for each imported case was assessed. We evaluated the relationship between the time to first reported importation and the Global Health Security Index (GHSI) overall score; 13,201 confirmed cases of COVID-19 were reported by 48 countries in SSA during the 54 days following the first known introduction to the region. Of the 2,516 cases for which travel history information was publicly available, 1,129 (44.9%) were considered importation events. Imported cases tended to be male (65.0%), with a median age of 41.0 years (range 6 weeks-88 years; IQR 31-54 years). A country's time to report its first importation was not related to the GHSI overall score, after controlling for air traffic. Countries in SSA generally reported with less publicly available detail over time and tended to have greater information on imported than local cases.The price of certain antiparasitic drugs (e.g., albendazole and mebendazole) has dramatically increased since 2010. The effect of these rising prices on treatment costs and use of standard of care (SOC) drugs is unknown. To measure the impact of drug prices on overall outpatient cost and quality of care, we identified outpatient visits associated with ascariasis, hookworm, and trichuriasis infections from the 2010 to 2017 MarketScan Commercial Claims and Encounters and Multi-state Medicaid databases using Truven Health MarketScan Treatment Pathways. Evaluation was limited to members with continuous enrollment in non-capitated plans 30 days prior, and 90 days following, the first diagnosis. The utilization of SOC prescriptions was considered a marker for quality of care. The impact of drug price on the outpatient expenses was measured by comparing the changes in drug and nondrug outpatient payments per patient through Welch's two sample t-tests. https://www.selleckchem.com/products/su056.html The total outpatient payments per patient (drug and nondrug), for the three parasitic infections, increased between 2010 and 2017. The increase was driven primarily by prescription drug payments, which increased 20.6-137.0 times, as compared with nondrug outpatient payments, which increased 0.3-2.2 times. As prices of mebendazole and albendazole increased, a shift to alternative SOC and non-SOC drug utilization was observed. Using parasitic infection treatment as a model, increases in prescription drug prices can act as the primary driver of increasing outpatient care costs. Simultaneously, there was a shift to alternative SOC, but also to non-SOC drug treatment, suggesting a decrease in quality of care.